Navigation Links
Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
Date:9/6/2007

Tanespimycin is the First Hsp90 Inhibitor to Enter Registration Trials

HAYWARD, Calif., Sept. 6 /PRNewswire-FirstCall/ -- Kosan Biosciences Incorporated (Nasdaq: KOSN) today announced that it has successfully reached a binding agreement with the U.S. Food and Drug Administration (FDA) on the design of its TIME-1 clinical trial, a pivotal Phase 3 trial of its Hsp90 inhibitor tanespimycin as a treatment for patients with multiple myeloma. Through the FDA's Special Protocol Assessment (SPA) process, Kosan and the FDA have reached agreement on overall protocol design, primary efficacy endpoints and data analysis as well as aspects of expected labeling if the data from the pivotal trial are supportive and tanespimycin is approved by the FDA. This pivotal Phase 3 protocol, as well as the overall development program, have also completed the "Scientific Advice" process with the centralized European Medicines Agency (EMEA).

Kosan's registration program for tanespimycin, called Tanespimycin in Myeloma Evaluation or TIME, has been initiated and includes two clinical trials: TIME-1 and TIME-2. TIME-1 is a pivotal Phase 3 trial to be conducted in a first-relapse patient population. TIME-1 will evaluate the clinical benefit of adding tanespimycin to bortezomib and compare these results to those seen with single-agent bortezomib. The Special Protocol Assessment Kosan has completed applies to the TIME-1 trial. TIME-2, which is designed to be supportive of the TIME-1 trial, is a Phase 2/3 trial in patients with relapsed-refractory disease. The TIME-2 trial also has the potential to support registration in the relapsed-refractory setting. Kosan has initiated the TIME-2 trial, which is enrolling patients, and expects to init
'/>"/>

SOURCE Kosan Biosciences Incorporated
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90 Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory Breast and Ovarian Cancers at ASCO
2. Kosan Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Epothilone KOS-1584 at ASCO
3. Kosan Presents Data on Lead Hsp90 Inhibitor, Tanespimycin, Showing Promising Antitumor Activity in Multiple Myeloma at ASCO
4. Kosan Presents Preliminary Phase 2 Data Showing Antitumor Activity of Hsp90 Inhibitor Tanespimycin in Metastatic Melanoma at ASCO
5. Kosan Presents Preclinical Data on Nuclear Export Inhibitors, Novel Anticancer Agents, at AACR
6. Kosan Presents Preclinical Antitumor and Safety Data On Next-Generation Epothilone KOS-1803 at AACR
7. Kosan Presents Data on Cardiac Safety Profile of Hsp90 Inhibitor Tanespimycin (KOS-953) at AACR
8. Kosan Announces Data Presentations at Upcoming AACR Annual Meeting
9. Sirion Therapeutics Receives Orphan Drug Designation for Ophthalmic Drug to Treat Viral Eye Infection
10. Protalix BioTherapeutics, Inc. Receives Approval from the FDA to Initiate a Phase III Clinical Trial of prGCD
11. DUSA Pharmaceuticals Receives Orphan Drug Desi gnation for Levulan PDT to Treat Esophage al Dysplasia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... CLEVELAND , Jan. 14, 2014 NineSigma ... will hold its Innovation Leadership Summit , May ... in Cleveland Ohio . ... innovators and organizations committed to breakthrough achievements through open ...
(Date:1/14/2014)... York , January 14, 2014 ... System Transfer Devices (CSTD) for hazardous drugs, today announced that ... the fourth straight year.   Equashield,s ... pharmacy technicians, pharmacists, nurses and other medical professionals ...
(Date:1/14/2014)... Therapeutics , a late-stage gene therapy company, has reached its patient ... study for inherited retinal dystrophies caused by mutations in the ... presenting this and other corporate updates today, at the 32nd Annual ... Marrazzo said Spark was able to achieve its recruitment goal a ...
Breaking Medicine Technology:Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 2Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 3Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 4Equashield's Sales Grow by 60% in 2013 2Spark Therapeutics Achieves Recruitment Goal in Phase 3 Gene Therapy Clinical Study for Inherited Blindness 2Spark Therapeutics Achieves Recruitment Goal in Phase 3 Gene Therapy Clinical Study for Inherited Blindness 3
... For the second consecutive year, the Exergen temporal artery ... stock the product, according to Nielsen and Information Resources ... including national brands and private label products, were compared. ... share has risen to 20 percent of all thermometers ...
... 2011 JLL Partners Inc. is pleased to announce ... PharmaNet Development Group, Inc. ("PharmaNet") to inVentiv Health, Inc. ... and inVentiv Health, Inc. is a leading global provider ... pharmaceutical and healthcare industries. Ramsey A. Frank, ...
Cached Medicine Technology:JLL Partners Sells PharmaNet 2
(Date:7/10/2014)... to 70% of Parkinson,s disease (PD) patients experience ... life. Some patients have disturbed sleep/wake patterns such ... other patients may be subject to sudden and ... patients may exhibit REM-sleep behavior disorder (RBD), characterized ... before motor symptoms appear. A review in the ...
(Date:7/10/2014)... at the University of Huddersfield could help to improve ... food products such as butter, mayonnaise, yoghurt and ... an international profile for her work. , Katerina gained ... the University and now she has embarked on research ... Vassilis Kontogiorgos, she is investigating the potential of carbohydrates ...
(Date:7/10/2014)... research review identifying the clinical indicators most strongly associated ... process of developing evidence-based guidelines for concussion diagnosis, prognosis, ... Neurosurgery , official journal of the ... is published by Lippincott Williams & Wilkins , ... , Based on analysis of the best available ...
(Date:7/10/2014)... Harbor, NY For decades, health-conscious people around the ... in antioxidants, figuring this was one of the paths ... , Yet clinical trials of antioxidant supplements have repeatedly ... to reduce their cancer risk. Virtually all such ... cancer. In fact, in several trials antioxidant supplementation ...
(Date:7/10/2014)... Biomedical Research Institute (IDIBELL) and the Catalan Institute of ... new therapeutic combination to combat resistant sarcomas. The clinical ... stabilize the growth of these tumors have been published ... ., Sarcomas , Sarcomas are a rare type ... It can affect from children to older ages. It ...
Breaking Medicine News(10 mins):Health News:Sleep disturbances, common in Parkinson's disease, can be early indicator of disease onset 2Health News:World interest in research work on the benefits of the Okra plant 2Health News:What's a concussion? Review identifies four evidence-based indicators 2Health News:What's a concussion? Review identifies four evidence-based indicators 3Health News:How antioxidants can accelerate cancers, and why they don't protect against them 2Health News:New therapeutic combination to slow resistant sarcomas 2
... led by an Indian American scientist have genetically engineered ... // ,Cotton fibre continues to be a globally ... source of protein, but the presence of the toxic ... ,To remove gossypol from cottonseeds, Keerti Rathore and ...
... an AIDS disaster and should get a control over the ... out of control //warned Ashok Alexander, the director of the ... official. ,According to Ashok Alexander who directs the $258-million ... said that the rising prevalence of HIV in more than ...
... South Kazakhstan has reached 80 with the recent death //of ... officials and non-governmental groups. It is believed that the five-year-old ... death. ,Chief physician of the regional HIV/ AIDS ... on Monday that a child infected with HIV was registered ...
... Between 2001 and 2006, the number of AIDS cases reported ... a formidable 61. //The increasing use of heroin has raised ... the spread of AIDS in the nation. , ,Anti-narcotics ... in Kabul has gone up from 7,000 in 2003, to ...
... by the Canadian MedicAlert Foundation.It now waives the fees ... special bracelet or necklet. , Children up ... allergies, asthma and diabetes in participating elementary schools will ... to this foundation about five per cent of children ...
... Researchers from Toronto, Canada have found that only a small ... not all the cells as believed earlier. // ,This ... have been found to be the source of the disease. ... This finding supports the view - stem cells may be ...
Cached Medicine News:Health News:India warned of Impending AIDS Disaster 2Health News:Cancer Stem Cells Alone spread Cancer 2
... part in our daily lives. But degenerative ... cause severe handicaps. A decisive consideration in ... to produce a reconstructed joint function that ... possible.,The cementless RM Finger System has proven ...
... The Low Profile Leg Holder provides precise control ... leg rotation, and maximum exposure of the proximal ... Profile Leg Holder can be used on both ... to different heights.,The Low Profile Leg Holder can ...
... knee during surgery. Slotted base allows the ... knee surgery. Slots are also designed to allow ... can be sterilized by either gas or steam ... can be clamped over the sterile drape to ...
... The True/Flex Upper Extremity Intramedullary Rod System ... alternative to conventional methods of rodding and ... micromotion at the fracture site and enhanced ... rods to be easily inserted into the ...
Medicine Products: